Strictly Come Dancing fans were left furious during the semi-final when they believed that Shirley Ballas was unfairly dishing out compliments and over-marking Pete Wicks . The ex-TOWIE star has made it through to the penultimate week without ever being in the dance-off - despite those considered superior dancers to him being eliminated along the way. In fact, just minutes into the show, fans were already venting their dismay on social media believing he didn't deserve to be there alongside fellow semi-finalists Chris McCausland, Tasha Ghouri , JB Gill and Sarah Hadland. And their frustrations escalated following Pete's first performance when head judge Shirley lavished him with praise even dubbing him 'Mr Strictly'. Shirley told Pete that she judged him on how he'd progressed during the competition rather than against anyone else. She said: "You are Mr Strictly Come Dancing . You are what this show is about. Everybody at home, all the parents, will be sitting there and thinking, 'if Pete can do it, I can do it' and you will inspire people to go to the dance studio. "You had no experience whatsoever coming in. I thought you did a very good job on your footwork and your neckline.... week one you were like this and today you were shining. You didn't make any mistakes, you did a grand job. You should walk with your head high - you are absolutely Mr Strictly Come Dancing." She went on to award him the highest mark of all the judges - nine out of 10 - giving him a total of 32 out of 40. But fans took exception to Shirley's lavish praise and rushed to social media platform X to call out her 'bias'. One said: "SHIRLEY CALLING PETE MR STRICTLY COME DANCING LIKE MONTELL DIDNT ALSO START FROM NOTHING BUT NEVER GOT THAT PRAISE. The bias is RIDICULOUS." A second said: "Sh*rley can retire after calling pete mr strictly come dancing after criticising tasha for coming out of lifts, it’s completely unfair to treat contestants so differently. Pete is not the first or last person to start at nothing NOT EVEN IN THIS SERIES." Another commented: "shirley calling pete “mr strictly come dancing” when he shouldn’t even be in the semi finals in the first place..." And: "Shirley acting like Pete is God’s gift to dancing and giving him a bloody 9." A fifth said: "Shirley giving that a 9?? I’ve defended her all series but scoring that the same as JB and Sarah? Please..." The semi-final followed last weekend's surprise dance-off which saw Olympian Montell Douglas and Tasha Ghouri in the bottom two with Montell eliminated after the judges' votes. Strictly Come Dancing is on BBC One and BBC iPlayer
PNC Financial Services Group Inc. Trims Holdings in Liberty Broadband Co. (NASDAQ:LBRDK)
FMC Corp. stock underperforms Friday when compared to competitors despite daily gainsUltimate luxury: Sneak peek inside the world’s largest sailing yacht
Stocks closed higher on Wall Street, giving the market its fifth gain in a row and notching another record high for the Dow Jones Industrial Average. The S&P 500 rose 0.3% Friday. The Dow added 1%, and the Nasdaq composite tacked on 0.2%. Retailers had some of the biggest gains. Gap soared after reporting quarterly results that easily beat analysts’ estimates. EchoStar fell after DirecTV called off its purchase of that company’s Dish Network unit. European markets closed mostly higher and Asian markets ended mixed. On Friday: The S&P 500 rose 20.63 points, or 0.3%, to 5,969.34. The Dow Jones Industrial Average rose 426.16 points, or 1%, to 44,296.51. The Nasdaq composite rose 31.23 points, or 0.2%, to 19,003.65. The Russell 2000 index of smaller companies rose 42.65 points, or 1.8%, to 2,406.67. For the week: The S&P 500 is up 98.72 points, or 1.7%. The Dow is up 851.52 points, or 2%. The Nasdaq is up 323.53 points, or 1.7%. The Russell 2000 is up 102.84 points, or 4.5%. For the year: The S&P 500 is up 1,199.51 points, or 25.1%. The Dow is up 6,606.97 points, or 17.5%. The Nasdaq is up 3,992.30 points, or 26.6%. The Russell 2000 is up 379.60 points, or 18.7%.
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) SOURCE Amgen
NASHVILLE, Tenn. (AP) — The right frame can freeze a moment in time, creating meaning for the masses from a fist pump over a bloodied ear , a bridge crumbled by a ship , towns shredded by nature , and a victory sealed with an on-field kiss . In 2024, photographers across the U.S. captured glimpses of humanity, ranging from a deeply divisive presidential election , to hurricanes and fires that ravaged communities, to campus protests over the war between Israel and Hamas in Gaza. The gallery from The Associated Press illustrates a new chapter of political history — the assassination attempt on former President Donald Trump , the moment President Joe Biden announced he would no longer run again , the campaign sprint by Vice President Kamala Harris in Biden’s place, and the raw emotion from voters during a grueling contest ultimately won by Trump . Hurricanes whipped through the country with devastating imagery, leaving a path of wreckage and death from Florida to Appalachia . After Hurricane Helene , Lake Lure in North Carolina was shown in a jarring photo covered in shards of debris thick enough to hide the surface of the water. Hurricane Milton ripped apart the roof of Tropicana Field in St. Petersburg, Florida, home to Major League Baseball’s Tampa Bay Rays. The scale of destruction experienced in some corners of the country in 2024 was hard to capture and might have been harder to fathom. That was the case when a container ship slammed into the Francis Scott Key Bridge in Baltimore, causing it to collapse and crumple around the vessel, killing construction workers on the bridge. As flames torched the landscape in California , another image captured firefighters and sheriff’s deputies pushing a vintage car away from a burning home. Elsewhere in California , one photo is aglow with bright orange flames, broken up only by the subtle features of an animal running through them. But hope also persevered in the face of devastation. In Helene’s aftermath , an image from Crystal River, Florida, shows Dustin Holmes holding hands with his girlfriend, Hailey Morgan, as they sloshed through floodwaters with her 4- and 7-year-old children to return to their flooded home. And in Manasota Key, Florida, a family was lit up by the glow of flashlights as they walked to check on their home damaged by Milton. Other photos from 2024 also grabbed the darkness and shadows to emphasize light: among them, a rocket liftoff and a total solar eclipse . And, yes, eclipse glasses were back in style for a shared moment of skygazing. But many other photos delivered a blast of color, from the spectrum of the northern lights across a Maine sky to a crew of workers wading into the deep-red of a Massachusetts cranberry bog . And, once again, Taylor Swift captured the country’s attention, even as a part of the crowd. She rushed down from the stands to kiss her boyfriend, Kansas City Chiefs tight end Travis Kelce, after the Chiefs won the AFC Championship , en route to another Super Bowl win.
Ola Suzanne Stowers Featured in Exclusive Online Interview: From Operations to Orchids
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen Best trending stories from the week. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. You may occasionally receive promotions exclusive discounted subscription offers from the Roswell Daily Record. Feel free to cancel any time via the unsubscribe link in the newsletter you received. You can also control your newsletter options via your user dashboard by signing in.NoneTHE Ministry of Youth Development and Sports recently organised a series of exciting road races to assess the resilience and skills of young athletes in a mini marathon format. Over the course of one week, the athletes engaged in fun-filled competitions, showcasing friendly rivalry while navigating challenging routes. Here are some of the key results from the Inter-Secondary School’s Road Race Competitions 2024: 1st Place – Isabella Emilien – Saint Lucia Sports Academy (SLSA) 2nd Place – Keihanna St. Juste – Micoud Secondary School (MSS) 3rd Place – Alana Alex – Vieux Fort Comprehensive Secondary School (VFCSS) 4th Place – Talia Taylor – Sir Arthur Lewis Community College (SALCC) 1st Place – Jousha Lubin – SALCC 2nd Place – Darvin Joseph – MSS 3rd Place – Ryhime Montoute – MSS 4th Place – Jershawn Mitchel – SLSA 1st Place – Kerrina Monero – VFCSS 2nd Place – Mc Kaylla Olivier – SALCC 3rd Place – Abigail Herman – Saint Joseph’s Convent (SJC) 4th Place – Sherelle Etienne – SLSA 1st Place – Benique Mann – Anse Ger – Institute School of Innovation and Technology 2nd Place – Alex Devaux – Saint Mary’s College SMC) 3rd Place – Omarion Edwin – SMC 4th Place – Tafari Martin – MSS 1st Place – Sheldon Willie – SLSA 2nd Place – Joshua Charles – SMC 3rd Place – Elias Auguste – Anse Ger – Institute School of Innovation and Technology 4th Place – Keshawn Olice – MSS 1st Place – Maiya Landers – VFCSS 2nd Place – Angelle Joseph – Clendon Mason Memorial Secondary School 3rd Place – Seraphine Williams – Beanefield Comprehensive Secondary School 4th Place – Aria Andrew – SLSA 1st Place – Aniya George – SJC 2nd Place – Kayleigh Landers – VFCSS 3rd Place – Najma Melchoir – SJC 4th Place – Aria Anotole – Castries Comprehensive Secondary School (CCSS) 1st Place – Tai Joseph – SLSA 2nd Place – Diallo Albert – SMC 3rd Place – Jaylan Mc Donald – SMC 4th Place – Donavan Pascal – Soufriere Comprehensive Secondary School